Fleury stock

FLRY3 · B3 · BRL

Compare Fleury
R$21.51Change from previous close: 0.00%

Close · November 22, 2026

Price history

+41.23% over the period

1 year: from R$15.23 (November 24, 2025) to R$21.51 (November 22, 2026), +41.23%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 22, 2026R$21.51
October 30, 2026R$20.47
September 30, 2026R$22.79
August 31, 2026R$19.68
July 31, 2026R$17.14
June 30, 2026R$15.40
May 29, 2026R$15.39
April 30, 2026R$16.08
March 31, 2026R$15.93
February 27, 2026R$16.82
January 30, 2026R$16.62
December 30, 2025R$15.00
November 28, 2025R$16.05
November 24, 2025R$15.23

At a glance

  • The company

    Provide diagnostic imaging, clinical analysis, fertility and infusion services in Brazil through two operating segments

  • Latest results

    Quarter to September 30, 2026 · EPS R$0.49 (estimate R$0.43)

TickerLandia's take on Fleury

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk lowR$13.90
52-wk highR$28.65

−24.92% from the 52-week high

Analysts · 12 analysts

Average targetR$21.99+2.24% vs. price

Buy 3 · Hold 7 · Sell 2 · Hold

TickerLandia Fingerprint: Fleury

Compared with similar companies: very low price, very strong momentum, and very high growth.

Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 317 Latin American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Fleury is priced as in the past and cheaper than similar companies

On the latest fiscal year's earnings (2025), Fleury's P/E today is 19.1, in line with the median of its last 10 fiscal years (19.8; between 10.7 and 33.3 from 2016 to 2025). Fleury's P/E (trailing 12 months): 15.0, −47% against the median of a group of 10 similar companies (28.6).

P/E compared with its history

Compared with 10 similar companies

Fleury's metrics compared with similar companies
MetricFleuryPosition in the groupBand
P/E (trailing 12 months)15.0Low
Forward P/E12.8Low
Operating margin16.0%Middle
ROE14.0%High
Debt/equity1.15High

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Fleury. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

R$2.32B

Latest quarter · Q2 2026

Net income

R$221.85M

Latest quarter · Q2 2026

Quarterly net margin

9.6%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
R$11.69B
P/E
15.0
EPS
R$1.43
Volume
5.53M
Daily trading
€18.91M
Dividend yield
1.54%
Last ex-dividend on August 12, 2026

How Fleury is changing

All results
  • Revenue grew 22.8% a year on average over the last 5 years

  • Operating margin fell from 16.6% to 15.1%

  • Shares outstanding up 62.3% in 5 years

Returns

Fleury returns with dividends

R$1,000 invested in Fleury 5 years ago, on November 22, 2021, would be worth R$1,617 today with dividends reinvested: +61.72% in total, +10.09% per year. On price alone it would be R$1,219 (+21.92%).

PeriodFleuryIbovespaR$1,000 becomes
1 month−22.68%−18.87%R$773
6 months+37.09%−5.58%R$1,371
Year to date+43.40%+3.26%R$1,434
1 year+52.30%+7.15%R$1,523
3 years+54.94%+32.01%R$1,549
5 years+61.72%+62.92%R$1,617
10 years+92.18%+168.55%R$1,922

Over the last 6 months it has done better than 84% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. Ibovespa: with dividends. Calculate your investment

The chart in detail

Fleury: technical analysis

Fleury shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 31.9% below its all-time closing high (R$31.59, February 5, 2020).

Trend
No clear trend
RSI (14 sessions)
46
Between 30 and 70
vs 200-session average
+17.90%

Support and resistance

Price areas where Fleury has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last priceR$21.51
  3. SupportR$21.36−0.70%2 touches, last on November 11, 2026
  4. SupportR$17.91−16.74%2 touches, last on April 14, 2026
  5. SupportR$16.89−21.48%2 touches, last on July 17, 2026

Volatility and risk

Over the last year it has moved roughly in line with the Ibovespa.

Beta (1 year) vs Ibovespa
1.16
Volatility (60 sessions, annualised)
59.7%
Largest fall in the last year
−28.87%

In session, November 22, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Fleury: seasonality

Average monthly price change over 17 years

+0.6%Jan−1.0%Feb−1.0%Mar+1.3%Apr+2.7%May+2.5%Jun+1.6%Jul+3.1%Aug+0.4%Sep−1.0%Oct+0.1%Nov+0.0%Dec

Over the last 17 years, the strongest month for Fleury has been August: +3.15% on average, positive in 12 years out of 17. The weakest has been February: −1.05% on average, positive in 7 years out of 17. November, the current month, has been positive in 6 years out of 16 (+0.10% on average).

Show chart data
MonthAverageMedianPositive years
January+0.62%+0.27%10 of 17
February−1.05%−1.12%7 of 17
March−0.98%−2.35%7 of 17
April+1.26%+0.53%9 of 17
May+2.73%+3.60%11 of 17
June+2.54%+5.63%12 of 17
July+1.58%+2.05%11 of 17
August+3.15%+2.99%12 of 17
September+0.44%−0.54%8 of 17
October−0.98%−2.00%6 of 17
November+0.10%−2.90%6 of 16
December+0.04%+0.97%9 of 16

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Fleury and its competitors

Diagnostic Medicine, one of the two segments of Fleury S.A. and its subsidiaries, centers on diagnostic imaging and clinical analysis, alongside fertility services and infusions, all provided in Brazil. The second segment, Integrated Medicine, groups medical services that include laboratory support, health management, orthopedics, ophthalmology, toxicological tests and assistance medicine. The group also runs a health platform, an immunobiological drug infusion center and ophthalmology service centers.

Headquarters
São Paulo, Brazil
Employees
32,000
Founded
1926
Chief executive
Jeane Tsutsui
Fleury and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
FleuryFLRY3$1.97B16.0%15.0+37.09%
Diagnosticos da AmericaDASA3$686.17M10.9%—+8.67%
DiagnostykaDIA$1.27B14.9%20.2−6.62%
DiaSorinDIA$4.21B22.3%28.6+14.88%
Sonic HealthcareSHL$7.13B9.3%17.6+17.41%
WuXi XDC Cayman2268$9.64B28.1%46.6+3.47%

Same industry or related industries, similar size. Compare Fleury with its competitors · Full profile